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We have isolated 3 cDNA clones encoding human IGF-II and a variant of IGF-II. The amino acid sequence 
encoded by the IGF-II cDNA is identical to the sequence previously described [( 1978) FEBS Lett. 89,283- 
2861. In the amino acid sequence predicted by the IGF-II variant cDNA, the Ser residue 29 in the B-domain 
has been replaced by an Arg-Leu-Pro-Gly sequence. The corresponding mRNAs probably arise by alterna- 
tive splicing of a common RNA precursor. The IGF coding region of the cDNA inserts is flanked by se- 
quences encoding asignal peptide and a carboxy-terminal peptide indicating that both human IGF-II and 
its variant are synthesized asprecursors. 
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1. INTRODUCTION 
The somatomedins (SM) or insulin-like growth 
factors (IGF) constitute a heterogeneous family of 
peptides with insulin-like and growth-promoting 
effects [l]. The amino acid sequences of the two 
main types of IGF in human serum, IGF-I - which 
is identical to SM-C [2] - and IGF-II - which is 
very similar to multiplication-stimulating activity 
in the rat [3] - show 62% homology [4,5]. 
However, these two somatomedins may have a 
quite different physiology. IGF-I levels in blood 
are much more under growth hormone control 
than IGF-II and, while both have mitogenic effects 
in vitro, there is suggestive vidence that IGF-II is 
more important in antenatal growth [6-81. We 
have reported the nucleotide sequence of a human 
liver cDNA encoding IGF-I/SM-C flanked by 
amino- and carboxy-terminal extensions, thus pro- 
viding evidence that IGF-I/SM-C is synthesized as 
a precursor [9]. We now report the isolation and 
+ To whom correspondence should be addressed 
characterization of 3 cDNAs, isolated from the 
same human liver cDNA library, encoding IGF-II 
as well as a variant of IGF-II. 
2. MATERIALS AND METHODS 
2.1. cDNA library 
The adult human liver cDNA library, which we 
also used for the isolation of the IGF-I/SM-C, was 
kindly provided by Dr D. Woods of Children’s 
Hospital Medical Center, Boston, MA, USA [lo]. 
2.2. Screening procedure 
As a probe for screening the library we used the 
BarnHI-PstI restriction fragment (540 base pairs) 
of the cDNA encoding human IGF-I/SM-C [9], 
which contains the entire coding sequence for this 
growth factor. This cDNA fragment was labeled 
with 32P by nick-translation [ 111. 
Colonies were grown on nitrocellulose filters, 
replicated and screened according to the colony 
hybridization method in [12] with minor modifica- 
tions. After overnight hybridization at 42°C in a 
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mixture containing 40% formamide, 5 x 
Denhardt’s solution (0.1% Ficoll, 0.1% poly- 
vinylpyrrolidone, 0.1% bovine serum albu- 
min), 0.75 M NaCl, 75 mM Na-citrate, 0.1% SDS 
and 100 pg/ml calf thymus DNA, the 
nitrocellulose filters were washed at 60°C in SSC 
(0.15 M NaCl, 15 mM Na-citrate) for 1 h and 
autoradiographed. Subsequently, they were 
washed in 0.3 x SSC at 60°C for r/2 h and again 
autoradiographed. 
2.3. Analysis of cDNA 
Plasmid cDNA was isolated according to the 
alkaline lysis method in [ 131. Nucleotide sequence: 
analysis was performed as in [14]. 
3. RESULTS 
The amino acid sequences of IGF-I/SM-C and 
IGF-II show 62% homology, hence the IGF-I/SM- 
C cDNA could be expected to cross-hybridize with 
IGF-II cDNA under conditions of reduced 
stringency. Four colonies were identified, showing 
hybridization to the 32P-labeled IGF-I/SM-C 
cDNA probe under such conditions. Only one of 
them still hybridized with the probe after the wash 
at increased stringency (0.3 x SSC, 60°C ‘/z h). 
Restriction endonuclease analysis of the plasmid 
isolated from this clone showed a pattern similar to 
that of the plasmid containing IGF-I cDNA [9]. 
The other 3 cDNA inserts were very similar to Fach 
other in their restriction pattern, but differ?.! ‘.I om 
that of the IGF-I/SM-C cDNA. These inser::, :A, 
B, C) were subjected to nucleotide se.,.;?nce 
analysis following the strategy depicted in fig.1. 
The nucleotide sequences of the cDNA strands 
homologous to the corresponding mRNAs are 
shown in fig.2. The 660 nucleotide long cDNA in- 
sert of clone A encodes the first 160 amino acid 
residues of human preproinsulin-like growth fac- 
tor II [15]. 
The nucleotide sequences of the cDNA inserts of 
clones B and C partially overlap and complement 
each other. The combined sequence comprises 846 
nucleotides, containing an open reading frame of 
650 nucleotides between the TGA termination 
codons at position - 103 and 550, respectively. 
The predicted amino acid sequence is identical to 
that of human pre-pro-IGF-II [15], with the excep- 
tion of the Ser residue at position 29 in the B- 
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Fig. 1. Organization and sequencing strategy for the 3 
cDNAs encoding IGF-II (A) and the IGF-II variant 
(B,C). The regions encoding the B, C, A and D-domains 
(higher open boxes) as well as those coding for the signal 
peptide and the C-terminal peptide (lower open boxes) 
are depicted schematically. The black bar in the B- 
domain of clones B and C indicates the nonanucleotide 
insert in the variant-IGF-II sequence. The 5’ and 3’ 
non-translated regions are hatched; asterisks indicate 
stopcodons. Of the restriction sites only those used for 
sequencing are indicated. The horizontal arrows indicate 
the direction and extent of the sequence determinations; 
single-headed arrows refer to clones B and C, whereas 
double-headed arrows indicate confirmatory deter- 
minations in clone A. 
domain of IGF-II [4], which has been replaced by 
the tetrapeptide Arg-Leu-Pro-Gly. We therefore 
refer to this 70 amino acid long IGF-II related pep- 
tide as an IGF-II variant. The nucleotide sequence 
is otherwise identical to that of clone A, as far as 
they overlap. These results indicate that the IGF-II 
variant is synthesized as a precursor with a total 
length of 183 amino acids, and an M, of 20477, 
while the IGF-II precursor is 180 amino acids long 
and has an M, of 20141. 
4. DISCUSSION 
From the same human liver cDNA library we 
have isolated two closely related but distinct types 
of cDNA encoding precursors of IGF-II and a 
variant of IGF-II. Both precursors appear to have 
identical amino-terminal and carboxyterminal pep- 
tides. During the preparation of this report, the 
complete nucleotide sequence of pre-pro-IGF-II 
was published [15] for another cDNA isolated 
Volume 179, number 2 FEBS LETTERS January 1985 
bA 
5'-TGGGAGGAGGTGGATTCCAGCCCCCAGCCCCAGGGCTCTGAATCGCTGCCAGCTCAGCCCCCTGCCCAGCCTGCCCCACAGCCTGAGCCCCAGCAGG 
)B do0 -1'50 
CCAGAGAGCCCAGTCCTGAGGieAGCTGCTGTGGCCTGTGGCCCAGGCGACCCCAGCGCTCCCAGAACTGAGGCTGGCAGCCAGCCCCAGCCTCAGCCCC~CTGC~GGCAGAGAGACACCA 
-1'oo -50 
-24 -20 -10 -1 1 
Met Gly Ile Pro Met Gly Lys Ser Met Leu Val Leu Leu Thr Phe Leu Ala Phe Ala Ser Cys Cys Ile Ala Ala Tyr Arg Pro Ser Glu Thr 
fiTG GGA ATC CCA ATG GGG AAG TCG ATG CTG GTG CTT CTC ACC TTC TTG GCC TTC GCC TCG TGC TGC ATT GCT GCT TAC CGC CCC AGT GAG ACC 
1 50 
IGF.II”‘” 
10 20 ,C 
Leu Cys Gly Gly Glu Leu Val Asp Thr Leu Gln Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe !, 
CTG TGC CjGC GGG GAG CTG GTG GAC ACC CTC CAG TTC GTC TGT GGG GAC CGC GGC TTF TAC TTC 
c Arg Pro Ala Ser Arg Val 
100 
AGG CCC GCA AGC CGT GTG 
150 A_____lK___GCl 
IGF.II 
40 (40) 50 (sol 60 60) 
Ser Arg Arg Ser Arg Gly Ile Val Glu Glu Cys Cys Phe Arg Ser Cys Asp Leu Ala Leu Leu Glu Thr Tyr Cys Ala Thr Pro Ala Lys Ser 
AGC CGT CGC AGC CGT GGC ATC GTT GAG GAG TGC TGT TTC CGC AGC TGT GAC CTG GCC CTC CTG FAG ACG TAC TGT GCT ACC CCC GCC AAG TCC 
200 QOOI 250 (250) 
70 m 80 QO) go 60) 100 
Glu Arg Asp Val Ser Thr Pro Pro Thr Val Leu Pro Asp Am Phe Pro Arg Tyr Pro Val Gly Lys Phe Phe Gln Tyr Asp Thr Trp Lys Gln 
G&AGG GAC GTG TCG ACC CCT CCG ACC GTG CTT CCG GAC AAC TTC CCC AGA TAC CCC GTG GGC AAG TTC TIC CAA TAT GeC ACC TGG AAG CAG 
3b0 ubo) 350 (350) 
(100) 110 (110 120 (120) 130 
Ser Thr Gln Arg Leu Arg Arg Gly Leu Pro Ala Leu Leu Arg Ala Arq Arg Gly HIS Val Leu Ala Lys Glu Leu Glu Ala Phe Arg Glu Ala 
TCC ACC CAG CGC CTG CGC AGG GGC CTG CCT GCC CTC CTG CGT GCC CGC CGG GGT CAC GTG CTC GCC AAG GAG CTC GAG GCG TTC AGC- GAG GCC 
460 @bo) 450 1450) 
(1 30) A4 140 150 
LYS Arq HIS Arg Pro Leu Ile Ala Leu Pro Thr Gln Asp Pro Ala HIS Gly Gly Ala Pro Pro Glu Met Ala Ser Asn Arg Lys 
160 
AAA CGT CAC CGT CCC CTG ATT GCT CTA CCC ACC CAA GAC CCC GCC CAC GGG GGC GCC CCC CCA GAG ATG GCC AGC AAT CGG AAG i:i GCAAAAC 
04 5bo 550 
TGCCGCAAGTCTGCAGCCCGGCGCCACCAlCClGCAGCCTCCTCCATCCCCCCCGCGCCCCCCGCAG-3' 
6bo CC 
Fig.2. Nucleotide sequence of the cDNA-inserts encoding human IGF-II and IGF-II variant. The DNA strand presented 
is homologous to the IGF-mRNAs. Nucleotides are numbered sequentially from the ATG codon encoding the Met 
residue at position - 24; nucleotides preceding this ATG codon are given negative numbers. The predicted amino acid 
sequence is numbered starting at the amino-terminus of the IGF-sequences (underlined); amino acid residues of the 
signal peptide are given negative numbers. Following the region in the B-domain where the sequences of IGF-II and 
its variant diverge, the amino acid and nucleotide numbers referring to IGF-II are bracketed. The black arrowheads 
plus letters indicate the determined sequences of the cDNA-inserts from clones A, B and C. The sequence between the 
open arrowheads represents the nonanucleotide insert in the IGF-II variant. Asterisks indicate the termination codons, 
TGA. 
from the same library. Both nucleotide sequences 
are identical, except for an additional C at position 
- 80, which brings the termination codon TGA at 
nucleotide position - 103 in the same reading 
frame as the initiation codon ATG as position 1. 
Comparison of the nucleotide sequences of the 
regions coding for IGF-II and the IGF-II variant 
demonstrates that the IGF-II variant cDNA con- 
tains a short insert of 9 nucleotides at nucleotide 
positions 158-166. Theoretically, the presence of 
two closely related cytoplasmic mRNAs in the 
original liver cells corresponding to both types of 
IGF-II can be explained by postulation of two 
separate genes for IGF-II and the variant. 
However, circumstantial evidence from chromo- 
somal mapping studies as performed by our group 
[ 161 as authors in [17] and [ 181 points to the ex- 
istence of only a single IGF-II gene. Another ex- 
planation might be that the two species of mRNA 
arise by alternative splicing of a common RNA 
precursor. The presence of a typical acceptor site 
(5 ‘-CTTCCAG-3 ‘) in the sequence of the extra 9 
nucleotides of the variant IGF-II cDNA strongly 
favors the latter explanation. Moreover, nucleo- 
tide sequence analysis of the IGF-II gene as 
reported in [I91 indicates the presence of an in- 
tervening sequence of approx. 1700 nucleotides ex- 
actly at this point, the A and G nucleotides of the 
245 
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AGC codon (Ser B 29) functioning as donor and 
acceptor splice site, respectively. The last 9 
nucleotides of this intron perfectly match the 
nonanucleotide insert in the IGF-II variant precur- 
sor. Whether this alternative splicing is tissue- 
specific is unknown and requires further 
investigation. 
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